natgillin/translations-raw huggingface dataset:
Please inform your doctor about all other medicines you are taking especially antidepressants, alpha- methyldopa (antihypertensive), apomorphine (used for Parkinson’ s disease), dobutamine (used in the management of congestive heart failure), adrenaline (used for heart attacks) and isoprenaline (used for heart attacks).
Jemanje drugih zdravil Prosimo obvestite svojega zdravnika o vseh ostalih zdravilih, ki jih jemljete, posebno o antidepresivih, alfa- metildopi (zdravilo za zdravljenje zvišanega krvnega tlaka), apomorfinu (za zdravljenje Parkinsonove bolezni), dobutaminu (za zdravljenje kongestivnega srčnega popuščanja), adrenalinu (pri srčni kapi) in izoprenalinu (pri srčni kapi).
When you are taking Tasmar with anticoagulants (that prevent blood clotting) of the warfarin type, your doctor may perform regular blood tests to monitor how easily the blood clots.
Če jemljete zdravilo Tasmar z antikoagulanti (preprečujejo strjevanje krvi) varfarinskega tipa, lahko vaš zdravnik predpiše redne krvne preiskave za spremljanje strjevanja krvi.
If you go to hospital or if you are prescribed a new medicine, you must tell your doctor that you are taking Tasmar.
Če greste v bolnišnico, ali vam je bilo predpisano novo zdravilo, morate zdravniku povedati, da jemljete zdravilo Tasmar.
Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed (non-prescription medications and herbals).
49 Prosimo, da svojemu zdravniku ali farmacevtu poveste, če jemljete ali ste pred kratkim jemali katero koli zdravilo, tudi če ste ga dobili brez recepta (zdravila, ki se izdajajo brez recepta in zdravila rastlinskega izvora).
HOW TO TAKE TASMAR
KAKO JEMATI ZDRAVILO TASMAR
Always take Tasmar exactly as your doctor has instructed you.
Pri jemanju zdravila Tasmar vedno natančno upoštevajte zdravnikova navodila.
You should check with your doctor if you are unsure.
Če ste negotovi, se posvetujte s svojim zdravnikom.
Do not break or crush tablets.
Ne lomite ali drobite tablet.
Dosage and Frequency of administration
Odmerjanje
When beginning and during treatment with Tasmar, your dose of levodopa may need to be changed.
Na začetku zdravljenja in med zdravljenjem z zdravilom Tasmar bo mogoče treba vaš odmerek levodope spremeniti.
Your doctor will advise you what to do.
To vam bo svetoval vaš zdravnik.
Your doctor should always begin your treatment with the standard dose (100 mg three times a day).
Vaš zdravnik naj bi vedno začel zdravljenje s standardnim odmerkom (100 mg trikrat na dan).
The dose should only be increased to the higher dose (200 mg three times a day) if the increase in how your Parkinson’ s disease symptoms are controlled outweighs the expected increase in side effects.
Odmerek naj se poveča (na 200 mg trikrat na dan) le, če povečan nadzor nad simptomi vaše Parkinsonove bolezni odtehta pričakovano povečanje neželenih učinkov.
The side effects at the higher dose can often be severe and affect your liver.
Neželeni učinki pri večjem odmerku so pogosto lahko hudi in prizadenejo vaša jetra.
Your doctor should perform a blood test to monitor your liver function before starting the treatment and regularly every 2 weeks thereafter for the first year of therapy, every 4 weeks for the next 6 months and every 8 weeks thereafter.
Vaš zdravnik mora narediti krvne preiskave, da bo nadzoroval delovanje vaših jeter pred začetkom zdravljenja in nato redno vsaka 2 tedna v prvem letu zdravljenja, vsake 4 tedne naslednjih 6 mesecev in vsakih 8 tednov zatem.
If your doctor increases your dose, the liver tests will have to be repeated before increasing the dose and regularly afterwards.
Če vam vaš zdravnik odmerek poveča, se morajo jetrni testi ponoviti pred povečanjem odmerka in nato redno med zdravljenjem.
The first dose of Tasmar is taken with the first dose of the day of levodopa and the other doses of Tasmar are taken about 6 and 12 hours later.
Prvi odmerek zdravila Tasmar se vzame s prvim dnevnim odmerkom levodope, ostala odmerka zdravila Tasmar pa približno 6 in 12 ur pozneje.
Take one tablet in the morning, one tablet in the middle of the day and one tablet in the evening.
Vzemite eno tableto zjutraj, eno tableto sredi dneva in eno tableto zvečer.
Tell your doctor if, for any reason, you have not taken your medicine exactly as prescribed.
Povejte svojemu zdravniku, če zdravila iz kakršnega koli vzroka niste jemali, kot vam je bilo predpisano.
Otherwise, your doctor may think that it was not effective or well tolerated and may change your treatment unnecessarily.
Vaš zdravnik lahko v nasprotnem primeru sklepa, da vaše zdravljenje ni bilo učinkovito ali dobro prenosljivo in vam po nepotrebnem zdravljenje spremeni.
Contact a doctor, pharmacist or hospital immediately as you may need urgent medical attention.
Če ste vzeli večji odmerek zdravila Tasmar, kot bi smeli Nemudoma stopite v stik z zdravnikom, farmacevtom ali bolnišnico, saj boste verjetno potrebovali takojšnjo medicinsko pomoč.
Symptoms of overdose may include nausea, vomiting, dizziness and breathing difficulties.
Simptomi čezmernega odmerjanja lahko vključujejo slabost, bruhanje, vrtoglavico in težave z dihanjem.
Take it as soon as you remember, then continue to take it at the usual times.
Če ste pozabili vzeti zdravilo Tasmar Vzemite ga takoj, ko se spomnite, potem z jemanjem nadaljujte ob običajnih časih.
If you have missed several doses, please inform your doctor and follow the advice given to you.
Če ste izpustili več odmerkov, prosimo obvestite svojega zdravnika in upoštevajte njegova navodila.
Do not reduce or stop taking your medicine unless your doctor tells you to.
Učinki, ko prenehate jemati zdravilo Tasmar Ne zmanjšajte odmerka in ne prenehajte jemati zdravila Tasmar, razen če vam to naroči zdravnik.
Like all medicines, Tasmar can have side effects.
Kot vsa zdravila ima lahko tudi zdravilo Tasmar neželene učinke.
Tell your doctor or a pharmacist as soon as possible if you do not feel well while you are taking Tasmar.
50 Če se med jemanjem zdravila Tasmar ne počutite dobro, to čim prej povejte svojemu zdravniku ali farmacevtu.
The unwanted effects that are most likely to occur are: dyskinesia (involuntary movement), nausea, sleeping problems, decreased appetite, diarrhoea, fainting, feeling lightheaded when you stand, constipation and hallucination.
Neželeni učinki, ki lahko najverjetneje nastanejo, so: diskinezija (nehoteno gibanje), slabost, težave s spanjem, zmanjšan apetit, driska, omedlevica, občutek vrtoglavice, ko stojite, zaprtje in halucinacije.
50 Disturbances in the way the liver works, sometimes severe hepatitis, have been observed.
Opažene so bile motnje v delovanju jeter, včasih hudi hepatitis.
Therefore, if you experience symptoms such as nausea, vomiting, abdominal pain, loss of appetite, weakness, fever, darkening of urine or jaundice you should contact your doctor immediately.
Zato morate, če dobite simptome, kot so slabost, bruhanje, bolečina v trebuhu, izguba apetita, šibkost, zvišana telesna temperatura, temnenje urina ali zlatenica, nemudoma stopiti v stik s svojim zdravnikom.
Soon after beginning and during your treatment with Tasmar, you may have symptoms caused by levodopa such as dyskinesia (involuntary movement) and nausea.
Kmalu po začetku zdravljenja ali med zdravljenjem z zdravilom Tasmar lahko dobite simptome, ki jih povzroča levodopa, kot so diskinezija (nehoteno gibanje) in slabost.
Therefore, if you feel unwell, you should contact your doctor since you may need to have your levodopa dose changed.
Če se ne počutite dobro, morate obiskati zdravnika, saj bo verjetno treba vaš odmerek levodope spremeniti.
Contact your doctor if you develop persistent or severe diarrhoea.
Obvestite zdravnika, če dobite dolgotrajno ali hudo drisko.
This medicine can cause a harmless yellow urine discoloration.
Zdravilo lahko povzroči razbarvanje rumenega urina, ki ni škodljivo.
However if you notice a darkening of your urine this could be a sign of muscle injury or liver injury, please inform your doctor.
Toda, če opazite temnenje urina, je to lahko znak za mišično poškodbo ali jetrno poškodbo, zato prosimo obvestite zdravnika.
Very rarely, patients develop Neuroleptic Malignant Syndrome (severe symptoms of muscle stiffening, fever or mental confusion) when antiparkinsonian treatments are abruptly reduced or withdrawn.
Zelo redko bolniki razvijejo maligni nevroleptični sindrom (resni simptomi mišične togosti, zvišana telesna temperatura ali zmedenost), ko se zdravila za zdravljenje parkinsonizma nenadno zmanjšajo ali ukinejo.
STORING TASMAR
SHRANJEVANJE ZDRAVILA TASMAR
Danmark MediLink A/ S Tlf: +45 70 22 30 15
51 Danmark MediLink A/ S Tlf: +45 70 22 30 15
51 Eesti Österreich (See Latvia)
Eesti Österreich (See Latvia)
52 PACKAGE LEAFLET
52 NAVODILO ZA UPORABO
Tasmar 200 mg film-coated tablet Tolcapone
Tasmar 200 mg filmsko obložena tableta tolkapon
- The active substance is tolcapone (200 mg in each film- coated tablet)
- Zdravilna učinkovina je tolkapon (200 mg v vsaki filmsko obloženi tableti).
Tasmar is an orange yellow to brown yellow, oval shaped, film-coated tablet. “ TASMAR” and “ 200” is engraved on one side.
Na eni strani tablete je vgravirano “ TASMAR ” in “ 200 ”.
Tasmar is supplied as film coated tablets containing 200 mg tolcapone.
Zdravilo Tasmar je v obliki filmsko obložene tablete, ki vsebuje 200 mg tolkapona.
53 Catechol-O-methyltransferase (COMT) is a natural enzyme in your body that breaks down the levodopa medication used to treat your Parkinson’ s disease.
53 Katehol- O- metiltransferaza (COMT) je naravni encim v vašem telesu, ki razgrajuje zdravilo levodopo, namenjeno zdravljenju vaše Parkinsonove bolezni.
Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed (non-prescription medications and herbals).
55 Prosimo, da svojemu zdravniku ali farmacevtu poveste, če jemljete ali ste pred kratkim jemali katero koli zdravilo, tudi če ste ga dobili brez recepta (zdravila, ki se izdajajo brez recepta in zdravila rastlinskega izvora).
Tell your doctor or a pharmacist as soon as possible if you do not feel well while you are taking Tasmar.
56 Če se med jemanjem zdravila Tasmar ne počutite dobro, to čim prej povejte svojemu zdravniku ali farmacevtu.
56 Disturbances in the way the liver works, sometimes severe hepatitis, have been observed.
Opažene so bile motnje v delovanju jeter, včasih hudi hepatitis.
Danmark MediLink A/ S Tlf: +45 70 22 30 15
57 Danmark MediLink A/ S Tlf: +45 70 22 30 15
57 Eesti Österreich (See Latvia)
Eesti Österreich (See Latvia)
What is TAXOTERE?
Kaj je zdravilo TAXOTERE?
TAXOTERE is a concentrate and solvent to be made up into a solution for infusion (drip into a vein).
Zdravilo TAXOTERE obsega koncentrat in vehikel, ki se pripravita v raztopino za infundiranje (infuzijo v veno).
What is TAXOTERE used for?
Za kaj se zdravilo TAXOTERE uporablja?
TAXOTERE is an anticancer medicine.
Zdravilo TAXOTERE je zdravilo proti raku.
It is used with cisplatin and 5-fluorouracil.
Uporablja se s cisplatinom in 5- fluoroacilom.
How is TAXOTERE used?
Kako se zdravilo TAXOTERE uporablja?
TAXOTERE should be used in specialised chemotherapy wards and it should only be given under the supervision of a doctor who is qualified in the use of anticancer chemotherapy.
Zdravilo TAXOTERE je treba uporabljati na specializiranih oddelkih za kemoterapijo in se sme dajati le pod nadzorom zdravnika, usposobljenega za uporabo kemoterapije proti raku.
TAXOTERE is only used when the neutrophil count (a type of white blood cell) is at least 1,500 cells/ mm3.
Zdravilo TAXOTERE se uporablja le, kadar število nevtrofilcev (vrste belih krvnih celic) znaša vsaj 1500 celic/ mm3.
Treatment with dexamethasone (an anti-inflammatory medicine) should be given to the patient on the day before treatment for prostate cancer or the day before and the two days after treatment for other types of cancer.
Pri zdravljenju raka prostate je treba na dan pred zdravljenjem bolniku dajati deksametazon (protivnetno zdravilo), medtem ko je treba pri zdravljenju ostalih vrst raka deksametazon bolniku dajati dan pred zdravljenjem in dva dni po njem.
TAXOTERE is given as a one-hour infusion every three weeks.
Zdravilo TAXOTERE se daje v obliki enourne infuzije vsake tri tedne.
The dose, length of treatment, and its use with other medicines depend on the type of cancer being treated.
Odmerek, trajanje zdravljenja in sočasna uporaba zdravila z drugimi zdravili so odvisni od vrste raka, ki se zdravi.
For more information, see the Summary of Product Characteristics.
Za več informacij glejte Povzetek glavnih značilnosti zdravila.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How does TAXOTERE work?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Kako zdravilo TAXOTERE deluje?
The active substance in TAXOTERE, docetaxel, belongs to the group of anticancer medicines known as the taxanes.
Zdravilna učinkovina zdravila TAXOTERE, docetaksel, spada v skupino zdravil proti raku, imenovanih taksani.
How has TAXOTERE been studied?
Kako je bilo zdravilo TAXOTERE raziskano?
TAXOTERE has been studied in a total of around 3,000 breast cancer patients, around 1,900 lung cancer patients, around 1,000 prostate cancer patients, 445 stomach cancer patients and 897 head and neck cancer patients.
Zdravilo TAXOTERE so preučevali pri približno 3. 000 bolnicah z rakom dojke, 1. 900 bolnikih s pljučnim rakom, 1. 000 bolnikih z rakom prostate, 445 bolnikih z želodčnim rakom in 897 bolnikih z rakom glave in vratu.
In most of these studies, TAXOTERE was combined with other anticancer treatments and compared with combinations of different treatments or the same treatment without TAXOTERE.
Pri večini teh študij so zdravilo TAXOTERE kombinirali z drugimi oblikami zdravljenja proti raku in ga primerjali s kombinacijami različnih oblik zdravljenja ali enakim zdravljenjem brez zdravila TAXOTERE.
The main measures of effectiveness were the response rates (percentage of patients whose cancer responded to treatment), the time taken for the disease to progress and the increase in survival time.
Glavna merila učinkovitosti zdravila so bili stopnja odziva (odstotek bolnikov, pri katerih se je rak odzval na zdravljenje), čas do napredovanja bolezni in podaljšanje časa preživetja.
What benefit has TAXOTERE shown during the studies?
Kakšne koristi je zdravilo TAXOTERE izkazalo med raziskavami?
The addition of TAXOTERE to other anticancer treatments produced significant increases in response rates, disease progression or survival in all five types of cancer (breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer).
Dodajanje zdravila TAXOTERE drugim oblikam zdravljenja proti raku je pokazalo pomembno povečanje stopnje odziva, napredovanja bolezni ali preživetja pri vseh petih vrstah raka (raku dojke, nedrobnoceličnem pljučnem raku, raku prostate, želodčnem adenokarcinomu in raku glave in vratu).
Used on its own in breast cancer, TAXOTERE was at least as effective as, and sometimes more effective than the comparator medicines.
Kadar se je uporabljalo kot monoterapija pri raku dojke, je bilo zdravilo TAXOTERE vsaj tako učinkovito kot primerjalna zdravila, včasih pa tudi bolj učinkovito kot primerjalna zdravila.
What is the risk associated with TAXOTERE?
Kakšna tveganja so povezana z zdravilom TAXOTERE?
The most common side effects in patients receiving TAXOTERE (seen in more than 1 patient in 10) are neutropenia (reduced white blood cell counts), anaemia (reduced red blood cell counts), thrombocytopenia (low blood platelet counts), febrile neutropenia (neutropenia with fever), peripheral sensory neuropathy (damage to the nerves causing numbness, tingling and pain in the hands and feet), peripheral motor neuropathy (damage to the nerves causing difficulty co-ordinating movements), dysgeusia (taste disturbances), dyspnoea (shortness of breath), stomatitis (inflammation of the lining of the mouth), diarrhoea, nausea (feeling sick), vomiting, alopecia (hair loss), skin reactions, nail disorders, myalgia (muscle pain), anorexia (loss of appetite), infections, fluid retention, asthenia (weakness), pain and hypersensitivity (allergic reactions).
Najpogostejši neželeni učinki pri bolnikih, ki prejemajo zdravilo TAXOTERE (opaženi pri več kot 1 bolniku od 10), so nevtropenija (zmanjšano število belih krvnih celic), anemija (zmanjšano število rdečih krvnih celic), trombocitopenija (nizko število trombocitov), febrilna nevtropenija (nevtropenija s povišano telesno temperaturo), periferna senzorična nevropatija (poškodbe živcev, katerih posledica je otrplost, mravljinčenje in bolečine v rokah in nogah), periferna motorična nevropatija (poškodbe živcev, ki otežujejo koordinacijo gibov), dizgevzija (motnje okušanja), dispneja (zasoplost), stomatitits (vnetje ustne sluznice), driska, navzeja (občutek slabosti), bruhanje, alopecija (izpadanje las), kožne reakcije, prizadetost nohtov, mialgija (bolečine v mišicah), anoreksija (izguba apetita), okužbe, zastajanje tekočine, astenija (šibkost), bolečine in preobčutljivost (alergične reakcije).
These side effects may be more severe when TAXOTERE is used with other anticancer medicines.
Kadar se zdravilo TAXOTERE uporablja z drugimi zdravili proti raku, so lahko ti neželeni učinki hujši.
For the full list of all side effects reported with TAXOTERE, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila TAXOTERE, glejte Navodilo za uporabo.
TAXOTERE should not be used in people who may be hypersensitive (allergic) to docetaxel or any of the other ingredients.
Zdravila TAXOTERE se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) docetaksel ali katerokoli drugo sestavino zdravila.
TAXOTERE should not be used in patients who have a neutrophil count of less than 1,500 cells/ mm3, in pregnant or breast-feeding women, or in patients who have severe liver disease.
Zdravila TAXOTERE se ne sme uporabljati pri bolnikih s številom nevtrofilcev, manjšim od 1. 500 celic/ mm3, pri nosečnicah ali ženskah, ki dojijo, ali pri bolnikih s hudo boleznijo jeter.
Why has TAXOTERE been approved?
Zakaj je bilo zdravilo TAXOTERE odobreno?
The Committee for Medicinal Products for Human Use (CHMP) decided that TAXOTERE’ s benefits are greater than its risks for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and squamous cell head and neck cancer.
Odbor za zdravila za uporabo v humani medicini (CHMP) meni, da so za zdravljenje raka dojke, nedrobnoceličnega pljučnega raka, raka prostate, želodčnega adenokarcinoma in raka skvamoznih celic v glavi in vratu koristni učinki zdravila TAXOTERE večji od z njim povezanih tveganj.
The Committee recommended that TAXOTERE be given marketing authorisation.
Odbor je priporočil odobritev dovoljenja za promet z zdravilom TAXOTERE.
TAXOTERE was originally authorised under ‘ Exceptional Circumstances’, because, for scientific reasons, limited information was available at the time of approval.
Zdravilo TAXOTERE je bilo prvotno odobreno pod „ izjemnimi okoliščinami “, saj so bile v času odobritve zaradi znanstvenih razlogov na razpolago le omejene informacije.
As the company had supplied the additional information requested, the ‘ Exceptional Circumstances ’ ended on 7 July 1998.
Ker je podjetje predložilo dodatne zahtevane informacije, so bile 7. julija 1998 „ izjemne okoliščine “ razveljavljene.
Other information about TAXOTERE:
Druge informacije o zdravilu TAXOTERE:
The European Commission granted a marketing authorisation valid throughout the European Union for TAXOTERE to Aventis Pharma S. A. on 27 November 1995.
Evropska komisija je dovoljenje za promet z zdravilom TAXOTERE, veljavno po vsej Evropski uniji, odobrila podjetju Aventis Pharma S. A. dne 27. novembra 1995.
The marketing authorisation was renewed on 27 November 2000 and 27 November 2005.
Dovoljenje za promet z zdravilom je bilo podaljšano dne 27. novembra 2000 in 27. novembra 2005.
The full EPAR for TAXOTERE is available here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo TAXOTERE je na voljo tukaj.
Concentrate and solvent
koncentrat in vehikel za intravenska uporaba raztopino za infundiranje
Intravenous use Concentrate: vial (glass)
koncentrat: viala (steklo) vehikel: viala (steklo)
Solvent: vial (glass)
koncentrat:
Solvent:
0, 5ml vehikel:
Concentrate and solvent Intravenous use for solution for infusion
koncentrat in vehikel za intravenska uporaba raztopino za infundiranje
Concentrate: vial (glass) Solvent: vial (glass)
koncentrat: viala (steklo) vehikel: viala (steklo)
2 ml Solvent:
2 ml vehikel:
Ref.
London, 20. novembra 2008 Sklic dok.
Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Taxotere/ Docetaxel Winthrop
Vprašanja in odgovori v zvezi z umikom vloge za spremembo dovoljenja za promet z zdravilom Taxotere/ Docetaxel Winthrop
On 14 November 2008, Sanofi-Aventis Pharma S. A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Taxotere/ Docetaxel Winthrop, to add the treatment of patients with operable breast cancer whose tumours overexpress HER2 in combination with trastuzumab, with or without carboplatin.
Družba Sanofi- Aventis Pharma S. A. je dne 14. novembra 2008 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za novo indikacijo za zdravilo Taxotere/ Docetaxel Winthrop, tj. za dodatek zdravljenja bolnic z operabilnim rakom dojke, katerega tumorji imajo čezmerno izražajo HER2, v kombinaciji s trastuzumabom in karboplatinom ali brez njega.
What is Taxotere/ Docetaxel Winthrop?
Kaj je zdravilo Taxotere/ Docetaxel Winthrop?
Taxotere/ Docetaxel Winthrop is a concentrate and solvent, which are made up into a solution for infusion (drip into a vein).
Zdravilo Taxotere/ Docetaxel Winthrop je koncentrat in vehikel, ki se uporabljata za pripravo raztopine za infundiranje (vnašanje po kapljicah v veno).
Taxotere/ Docetaxel Winthrop is an anticancer medicine.
Taxotere/ Docetaxel Winthrop je zdravilo proti raku.
It is used in breast cancer that is advanced or ‘ metastatic’ (has spread to other parts of the body), and in breast cancer that can be treated with surgery.
Uporablja se pri raku dojke, ki je napredoval ali ima zasevke (se je razširil na druge dele telesa), ter pri raku dojke, ki ga je možno zdraviti z operativnim posegom.
In these patients, Taxotere/ Docetaxel Winthrop is used in addition to surgery to remove the tumour, together with doxorubicin and cyclophosphamide (other anticancer medicines).
Pri teh bolnicah se zdravilo Taxotere/ Docetaxel Winthrop uporablja kot dodatek operativnemu posegu za odstranitev tumorja skupaj z doksorubicinom in ciklofosfamidom (drugi dve zdravili proti raku).
Taxotere/ Docetaxel Winthrop is also used in advanced or metastatic non-small cell lung cancer, in prostate cancer, in metastatic gastric adenocarcinoma (a type of stomach cancer) and in advanced head and neck cancer.
Zdravilo Taxotere/ Docetaxel Winthrop se uporablja tudi pri napredovalem ali metastatskem nedrobnoceličnem pljučnem raku, raku prostate, metastatskem adenokarcinomu želodca (vrsta želodčnega raka) in pri napredovalem raku glave in vratu.
What was Taxotere/ Docetaxel Winthrop expected to be used for?
Za kaj naj bi se zdravilo Taxotere/ Docetaxel Winthrop uporabljalo?